Key result
Three-month telmisartan therapy significantly increased serum high molecular weight adiponectin levels by 16.4% and reduced blood pressure in Japanese male hypertensive subjects with abdominal obesity.
Why the study?
Does telmisartan improve HMW-adiponectin levels and blood pressure in male hypertensive subjects with abdominal obesity?
Observational (n=19)
No
Does telmisartan improve HMW-adiponectin levels and blood pressure in male hypertensive subjects with abdominal obesity?
Effect estimate: +16.4%
Absolute Event Rate: 2.4% vs 2.06%
p-value: p=0.017
Telmisartan effectively lowers blood pressure and increases serum HMW-adiponectin levels in male hypertensive patients with abdominal obesity, suggesting potential metabolic benefits.
May support metabolic benefits in obese male hypertensives; hypothesis-generating and requires RCTs before practice change.
AIM: Telmisartan, an angiotensin II receptor blocker (ARB), was reported to have partial peroxisome proliferator-activated receptor gamma (PPAR gamma) activity in vitro. Also, adipocyte-derived protein adiponectin, especially its high molecular weight (HMW) form, has been reported to have beneficial effects on insulin resistance and atherosclerosis. We investigated the effects of 3-month telmisartan therapy on various metabolic parameters, including serum HMW adiponectin and high-sensitivity C-reactive protein (hs-CRP) levels in male hypertensive subjects with abdominal obesity. METHODS: This study included 19 Japanese male hypertensive subjects, aged 51.2+/-7.6 (mean+/-SD) years, and body mass index 27.7+/-4.1 kg/m(2). In these subjects, 14 were naive to telmisartan treatment (40.0+/-15.7 mg daily), and 5 were changed from other ARBs to telmisartan. Serum HMW adiponectin concentration was assayed using HMW-selective ELISA kit. RESULTS: In all 19 subjects, systolic/diastolic blood pressure (BP) decreased from 153/98 to 134/85 mmHg (p<0.001 for both). Serum HMW-adiponectin level increased from 2.06+/-0.81 to 2.40+/-0.96 microg/mL (+16.4%, p=0.017). Body weight, glucose, insulin, lipids and hs-CRP did not change during the study period, and there were no adverse effects in any subject. In the newly administered group (n=14), the results were almost the same: BP decreased from 155/98 to 134/84 mmHg (p=0.0015 for both), and serum HMW-adiponectin level increased from 2.07+/-0.68 to 2.39+/-0.99 microg/mL (+15.5%, p=0.089). CONCLUSION: These data suggest that telmisartan therapy is efficient for controlling BP, and may exert beneficial effects on HMW adiponectin in male hypertensive subjects with abdominal obesity.
No takes yet. Share an insight, caveat, or question.
Komiya et al. (2009) conducted an observational in Hypertension with abdominal obesity (n=19). Telmisartan vs. Baseline was evaluated on Serum HMW-adiponectin level (μg/mL) (+16.4%, p=0.017). Three-month telmisartan therapy significantly increased serum high molecular weight adiponectin levels by 16.4% and reduced blood pressure in Japanese male hypertensive subjects with abdominal obesity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: